IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Artificial intelligence, Durg development, Drug discovery, clinical trial

RAJAN PRAJAPATI[1], ADITYA GUPTA[2], JAYANT KUMAR MAURYA[3],

1. Research Scholar, Ashok Singh Pharmacy College Maharoopur Jaunpur U.P. 222180
2. Assistant Professor, Department of Pharmacology Ashok Singh Pharmacy College Maharoopur Jaunpur U.P. 222180
3. Principal, Ashok Singh Pharmacy college Maharoopur Jaunpur U.P. 222180

Abstract: The current surge in machine learning and artificial intelligence has been truly remarkable, bringing about a substantial transformation. It has not only alleviated the burden on human labor but has also significantly enhanced the quality of life. This captivating article delves into the extraordinary utilization of machine learning and artificial intelligence to enhance the process of drug discovery and development, rendering it more efficient and precise. Within this study, a meticulous evaluation of various research endeavors was conducted. These studies were meticulously chosen based on the profound expertise of the authors and a comprehensive keyword search in publicly accessible databases. The selection process involved filtering the studies based on their contextual relevance, abstract, methodology, and full text. This comprehensive collection of works unequivocally encourages the pivotal roles played by artificial intelligence and machine learning in expediting the drug development and discovery processes. Moreover, these technologies have proven to be remarkably cost-effective, even eliminating the necessity for extensive clinical trials by enabling the simulation of various scenarios. They also serve as a resounding testament to the promising future that awaits these technologies, offering students, researchers, and the pharmaceutical industry an unprecedented opportunity to delve deeper into the realms of artificial intelligence and machine learning within the context of development and drug discovery.

Keywords: Artificial intelligence, Durg development, Drug discovery, clinical trial.

INTRODUCTION

Artificial intelligence is an exquisite amalgamation of diverse intelligent processes and behaviors, meticulously crafted by algorithms, computational models, or a meticulous a collection of guidelines. This extraordinary creation empowers machines to emulate the cognitive functions of humans, encompassing the realms of learning, problem-

solving, and beyond. AI has swiftly permeated the realm of healthcare, leaving an indelible mark on automation, disease diagnostics, and clinical decision-making. Within the vast expanse of pharmaceutical and healthcare research, AI presents boundless opportunities for exploration. Its unparalleled ability to delve into copious amounts of data from various modalities has opened new avenues for innovation. Numerous studies have shed light on the remarkable Artificial intelligence in healthcare and illuminating its potential to revolutionize the industry.

The healthcare industry has embraced a plethora of AI technologies, including the marvels of Physical robots, natural language processing (NLP), and machine learning (ML), and robotic process automation. In the realm of Deep learning, neural networks, and machine learning techniques adorned with an array of features have been harnessed to scrutinize imaging data. This meticulous analysis aids in the identification of components that are clinically significant, particularly in the initial phases of diagnoses connected to cancer. The marriage of AI and healthcare has birthed a new era of possibilities, where the boundaries of innovation are pushed to unprecedented heights. As AI continues to evolve and refine its capabilities, the future holds immense promise for the transformation of healthcare and the betterment of humanity**.**

NLP employs computational methods to understand the intricacies of human communication and extract its profound meaning. In recent times, ML techniques have been seamlessly integrated into NLP, enabling the exploration of unstructured data within databases and records such as doctors' notes, lab reports, and other invaluable sources. By extracting essential information from diverse textual and visual data, these techniques facilitate informed decision-making in diagnosis and treatment options, ushering in a new era of disruptive innovation.

This groundbreaking progress paves the way for patients to receive precise and expeditious diagnoses, coupled with tailored interventions for therapy. AI-driven solutions have emerged, encompassing platforms that harness a multitude of data types, including patient-reported symptoms, imaging, biometrics, and biomarkers. With the remarkable advancements in AI, the ability to detect potential illnesses well in advance becomes a reality, significantly enhancing the likelihood of prevention at the earliest stages.

Moreover, physical robots have found their place With a range of medical domains, surgical procedure, spanning nursing, cleaning, telemedicine, radiology and rehabilitation. Leveraging the power of robotic automation of processes, these robots utilize cost-effective and easily programmable technology to execute structured digital tasks, serving as semi-intelligent users within administrative systems. This remarkable technology can also be seamlessly integrated with image recognition, further augmenting its capabilities.

Within The medical system, repetitive tasks such as prior permission, patient record updates, and billing can greatly benefit from this technology, streamlining administrative processes and optimizing efficiency. Embracing these cutting-edge advancements, the healthcare industry embarks on a transformative journey towards a future where precision, speed, and innovation converge harmoniously.

The following domains see the application of artificial intelligence (AI).

- Trial, patient compliance, and endpoint identification monitoring.Disease diagnosis.
- Pandemic/epidemic forecasting.
- Individualized/digital therapy.

- Radiation treatment.
- Retina.
- Patient identification, recruiting, enrollment, and trial design for clinical trials.
- Cancer.
- Other chronic disorders.

- Drug finding.
  - Bioactivity and toxicity prediction.
  - Clinical trials.

Artificial Intelligence's Trending Use in the Pharmaceutical Sector:

In recent years, the utilization of artificial intelligence in the esteemed pharmaceutical and biological sector has transcended the realm of mere imagination and become an undeniable reality. Distinguished pharmaceutical and biotechnology enterprises are progressively embracing more streamlined and automated methodologies that encompass data-driven decision-making and employ cutting-edge tools for predictive analytics. The next phase in the development of this sophisticated data analysis strategy involves the integration of machine learning and artificial intelligence. The primary objective of this remarkable AI technicis to unveil concealed designs and extract invaluable insights from colossal volumes of data in manners that surpass human capabilities. The implementation of AI for data mining and analytics has already commenced a profound transformation across numerous industries, including the esteemed realms of pharmaceuticals and biotechnology. Its applications span a wide spectrum, ranging from revolutionary drug discovery to the automation of production processes, and even extend to medical uses like the utilization of robotic surgery and medical imaging.

Types of Artificial Intelligence

Most of the cutting-edge artificial intelligence solutions employed in the realm of healthcare today are founded upon meticulously crafted data science algorithms. This particular breed of AI harnesses the power of multivariate data analytics, fortified by a wealth of past experiential evidence. It ingeniously amalgamates population-based therapy results combined with the clinical information and medical background of each patient, thereby birthing a plethora of treatment alternatives and recommending the most efficacious drug combinations.

Venturing further into the realm of AI, we encounter the realm of machine learning, which relies upon the intricate workings of neural networks that artfully mimic the intricate machinations of the human brain. However, these neural networks possess the remarkable ability to reach decisions with unparalleled speed and accuracy. Machine learning, in its essence, is driven by data-driven algorithms that empower software applications to astutely predict outcomes without the need for explicit programming.

Yet, there exists a realm beyond machine learning, a realm known as deep learning. Deep learning, too, is rooted in the realm of neural networks, but it transcends the boundaries of its predecessor. It encompasses a harmonious fusion comprises distinct computational layers, interwoven using merged signals. This extraordinary form of AI holds immense potential in the field of diagnostics, as it possesses the uncanny ability to meticulously analyze images, such as photographs depicting various skin disorders or radiological scanning. When coupled including information on pathology and past treatment results, deep learning becomes an indomitable force, capable of delivering unparalleled accuracy and precision.

The biopharmaceutical industry is presently using AI in a number of ways, including:

- **Improving the manufacturing process**

In the realm of development and production, the utilization of AI presents a plethora of opulent prospects to enhance various processes. AI possesses the remarkable ability to execute quality control, expedite design time, curtail materials wastage, enhance production reutilization, conduct predictive maintenance, and so much more. AI, in its multifaceted nature, can be harnessed in myriad ways to elevate the industrial process' efficiency, producing expeditious output and minimizing superfluous waste. As an illustrious example, a process that conventionally depends on human involvement for process data entry or management can be seamlessly accomplished through the implementation of CNC (computer numerical control).

FIGURE 1.1 Manufactruring of drug.

- **Drug development and discovery**

AI is revolutionizing the realm of pharmaceuticals, from the creation of exquisite molecules to the revelation of uncharted biological targets. Its influence extends to the identification and validation of drug targets, encompassing target-based, phenotypic, and multi-target drug discoveries, as well as the repurposing of existing drugs and the identification of biomarkers. The paramount advantage bestowed upon pharmaceutical companies by AI lies in its potential, particularly when integrated into drug trials, to expedite the approval process and hasten the arrival of drugs to the market. This remarkable capability translates into substantial cost savings, potentially leading to more affordable medications for patients and an expanded array of treatment options.

- **Handling clinical and biomedical data processing.**

Undoubtedly, the pinnacle of AI's advancement lies in the sophisticated algorithms meticulously crafted to peruse, categorize, and decipher copious amounts of textual information. This remarkable feat proves to be an opulent time-saving marvel for esteemed researchers within the realm of life sciences. By harnessing the power of AI, they are bestowed with an expedited and streamlined approach to scrutinize the colossal reservoirs of data emanating from the ever-expanding compendium of research publications.

4.Choosing participants for clinical trials:

In addition to its invaluable contribution in deciphering clinical trial data, artificial intelligence serves another purpose in the realm of pharmaceuticals - the identification of suitable patients to partake in these trials. Through the utilization of cutting-edge predictive analytics, AI possesses the capability to scrutinize genetic information, thereby discerning the ideal patient group for a given trial, while simultaneously determining the most ideal amount of samples. Furthermore, certain AI technologies possess the remarkable ability to comprehend and analyze unstructured data, including patients' free-form text input in clinical trial apps and physicians' notes and intake documents.

Figure1.3 drug development.

5.Drug compliance and quantity

Ensuring adherence to a procedure for drug studies among willing individuals taking part in clinical trials poses a significant challenge for pharmaceutical companies. Should patients deviate from the trial guidelines, they must either be excluded from the study or face the potential compromise of the drug study outcomes. A pivotal aspect of a triumphant drug trial lies in guaranteeing that participants consume the stipulated dosage of the investigated medication at the designated intervals. Hence, the paramount significance of establishing a mechanism to ensure drug

adherence cannot be overstated. By means of remote monitoring and sophisticated algorithms for scrutinizing test outcomes, artificial intelligence possesses the ability to distinguish the compliant individuals from the non-compliant, thereby separating the wheat from the chaff.

AI in Customized Therapy and Digital Therapy:

AI possesses the inherent capability to extract profound correlations from raw datasheets, thereby enabling its application in the diagnosis, treatment, and mitigation of diseases. In this burgeoning field, a plethora of advanced techniques are employed for computational comprehension, with the potential to revolutionize every facet of medical science. The intricate clinical challenges that necessitate resolution are met with the arduous task of analyzing, acquiring, and implementing vast reservoirs of knowledge. The advent of participants in medical trials proven to be a boon for clinicians, empowering them to unravel complex clinical enigmas. Systems such as evolutionary computational models, Artificial Neural Networks (ANNs), fuzzy expert systems, and hybrid intelligent systems serve as invaluable tools for healthcare professionals, facilitating seamless manipulation of data. The ANN, inspired by the intricate workings of the biological nervous system, operates through a system of linked computer processors called neurons that process data in parallel by performing computations.

Every neuron is intricately linked through connections imbued with weight in numbers, forming a complex web of information exchange. In 1974, Paul Werbos made the introduction a groundbreaking technique known as " Recursive learning." which revolutionized the field by providing An appropriate learning algorithm. The ANN has found extensive application in diverse domains such as diagnostic data interpretation, image analysis, and waveform analysis.Fuzzy logic, a realm of thinking, reasoning, and inference, possesses the remarkable ability to comprehend and utilize real-world phenomena. Its integration into AI systems further enhances their capacity to tackle complex medical challenges with unparalleled precision and efficacy.



Figure 1.4.AI in acquiring and analyzing data of a patient in personalizing the treatment.

AI are mostly use in:

- AI in Radiotherapy.
- AI in Cancer.
- AI in Retina.
- AI in Other Chronic Diseases.

Artificial Intelligence in Drug Development:

1. The lack of appropriate technologies hinders the evolution of a vast quantity of medicinal compounds found in the chemical space, but this can be overcome by leveraging AI in the process of developing new drugs.
2. The forecasting activities of various parameters, like log D or log P, are influenced by the quantitative structure-activity relationship, which enables forecasts and generation using computer programs.
3. The characteristics and 3D dispersion of molecules and their properties allows for the delocalization of molecules in the enormous space, enhancing the drug development process.
4. To showcase the bioactivity of molecules, It is suggested that to gather earlier data about placement and selectivity using reputable domains like PubChem, ChemBank,
5. Virtual screening through in silico methods offers improved analysis, quicker elimination, and assortment, enhancing the drug discovery process.
6. A variety of physicochemical characteristics are important. in increasing the effectiveness and biological activity of drugs.
7. AI-based QSAR approaches, such as QSAR, hold great potential for the application of drug candidates, offering a more efficient and accurate drug development process.
8. Traditional approaches to obtaining statistical differences in biological activity can be time-consuming, taking up to a decade to control. AI-based methods can significantly expedite this process.

Discussion and Conclusions:

In summary, the successful integration of AI and machine learning into drug discovery and development, as well as the pharmaceutical industry's endeavors in drug screening, ploy pharmacology, drug design, and drug repurposing, are influenced by numerous factors. Technological advancements, particularly those rooted in AI, will perpetually be necessary to streamline the research, development, and production processes, while simultaneously enhancing efficiency and reducing expenditures. This comprehensive review of existing literature has unequivocally demonstrated that AI and machine learning possess the potential to significantly enhance the efficacy and precision of development and drug discovery. These cutting-edge technologies not only optimize procedural efficiency but also, in certain instances, obviate the need for clinical trials by conducting simulations in their stead. Moreover, they enable researchers to conduct more extensive molecular studies without the need for trials, thereby diminishing costs and alleviating ethical concerns. The integration of AI and machine learning is poised to revolutionize drug development in due course, although several obstacles, such as the cleansing of unstructured and heterogeneous datasets and occasional limitations of computing devices, may impede progress. Once these barriers are surmounted, the implementation and refinement of AI and machine learning will be more widespread, heralding the advent of a new era for the pharmaceutical industry.

REFERENCE

1. Chen, M.; Decary, M. Artificial intelligence in healthcare: An essential guide for health leaders. In Healthcare Management Forum; SAGE Publications: Los Angeles, CA, USA, 2020.
2. Bajwa, J.; Munir, U.; Nori, A.; Williams, B. Artificial intelligence in healthcare: Transforming the practice of medicine. Future. Health. J. 2021, 8, e188–e194.
3. Sunarti, S.; Rahman, F.F.; Naufal, M.; Risky, M.; Febriyanto, K.; Masnina, R. Artificial intelligence in healthcare: Opportunities and risk for future. Gac. Sanit. 2021, 35, S67–S70.
4. Toepper, M. Dissociating Normal Aging from Alzheimer's Disease: A View from Cognitive Neuroscience. J. Alzheimer's Dis. 2017, 57, 331–352.

5. Davenport, T.; Kalakota, R. The potential for artificial intelligence in healthcare. Futur. Healthc. J. 2019, 6, 94–98.
6. Fakoor, R.; Ladhak, F.; Nazi, A.; Huber, M. Using deep learning to enhance cancer diagnosis and classification. In Proceedings of the International Conference on Machine Learning, Atlanta, GA, USA, 16–21 June 2013; ACM: New York, NY, USA, 2013; Volume 28, pp. 3937–3949.
7. Vial, A.; Stirling, D.; Field, M.; Ros, M.; Ritz, C.; Carolan, M.; Holloway, L.; Miller, A.A. The role of deep learning and radiomic feature extraction in cancer-specific predictive modelling: A review. Transl. Cancer Res. 2018, 7, 803–816.
8. Esteva, A.; Robicquet, A.; Ramsundar, B.; Kuleshov, V.; Depristo, M.; Chou, K.; Cui, C.; Corrado, G.; Thrun, S.; Dean, J. A guide to deep learning in healthcare. Nat. Med. 2019, 25, 24–29.
9. Horgan, D.; Romao, M.; Morré, S.A.; Kalra, D. Artificial Intelligence: Power for Civilisation—And for Better Healthcare. Public Health Genom. 2019, 22, 145–161.
10. Hussain, A.; Malik, A.; Halim, M.U.; Ali, A.M. The use of robotics in surgery: A review. Int. J. Clin. Pract. 2014, 68, 1376–1382.
11. Khan, Z.H.; Siddique, A.; Lee, C.W. Robotics Utilization for Healthcare Digitization in Global COVID-19 Management. Int. J. Environ. Res. Public Health 2020, 17, 3819.
12. Ribeiro, J.; Lima, R.; Eckhardt, T.; Paiva, S. Robotic Process Automation and Artificial Intelligence in Industry 4.0—A Literature review. Procedia Comput. Sci. 2021, 181, 51–58.
13. Paul, D.; Sanap, G.; Shenoy, S.; Kalyane, D.; Kalia, K.; Tekade, R.K. Artificial intelligence in drug discovery and development. Drug Discov. Today 2021, 26, 80–93.
14. Bhatt, A. Artificial intelligence in managing clinical trial design and conduct: Man and machine still on the learning curve? Perspect. Clin. Res. 2021.
15. Sahu, A.; Mishra, J.; Kushwaha, N. Artificial Intelligence (AI) in Drugs and Pharmaceuticals. Comb. Chem. High Throughput Screen. 2022, 25, 1818–1837.
16. Thakur, A.; Mishra, A.P.; Panda, B.; Rodríguez, C.S.; Gaurav, I.; Majhi, B. Application of Artificial Intelligence in Pharmaceutical and Biomedical Studies. Curr. Pharm. Des. 2020, 26, 3569–3578.
17. Menschner, P.; Prinz, A.; Koene, P.; Köbler, F.; Altmann, M.; Krcmar, H.; Leimeister, J.M. Reaching into patients' homes— Participatory designed AAL services: The case of a patient-centered nutrition tracking service. Electron. Mark. 2011, 21, 63–76.
18. Okoli, C. A Guide to Conducting a Standalone Systematic Literature Review. Commun. Assoc. Inf. Syst. 2015, 37, 879–910.
19. Paré, G.; Trudel, M.-C.; Jaana, M.; Kitsiou, S. Synthesizing information systems knowledge: A typology of literature reviews. Inf. Manag. 2015, 52, 183–199.
20. Grant, M.J.; Booth, A. A typology of reviews: An analysis of 14 review types and associated methodologies. Health Inf. Libr. J. 2009, 26, 91–108.
21. Ransohoff, D.F.; Feinstein, A.R. Problems of Spectrum and Bias in Evaluating the Efficacy of Diagnostic Tests. N. Engl. J. Med. 1978, 299, 926–930.
22. Jutel, A. Sociology of diagnosis: A preliminary review. Sociol. Health Illn. 2009, 31, 278–299. Chang, C.L.; Hsu, M.Y. The study that applies artificial intelligence and logistic regression for assistance in differential diagnostic of pancreatic cancer. Expert Syst. Appl. 2009, 36, 10663–10672
23. Obeng, O.; Paul, S. Understanding HIPAA compliance practice in healthcare organizations in a cultural context. In Proceedings of the 25th Americas Conference on Information Systems 2019, Cancún, Mexico, 15–17 August 2019.
24. Spohrer, J.; Banavar, G. Cognition as a Service: An Industry Perspective. AI Mag. 2017, 36, 71–86.
25. Nasirian, F.; Ahmadian, M.; Lee, O. AI-Based Voice Assistant Systems: Evaluating from the Interaction and Trust Perspectives. In Proceedings of the 23rd Americas Conference on Information Systems 2017, Boston, MA, USA, 10–12 August 2017.

26. Dellermann, D.; Lipusch, N.; Ebel, P.; Leimeister, J.M. Design principles for a hybrid intelligence decision support system for business model validation. Electron. Mark. 2019, 29, 423–441.
27. Kersting, K. Machine Learning and Artificial Intelligence: Two Fellow Travelers on the Quest for Intelligent Behaviour in Machines. Front. Big Data 2018, 1, 6.
28. Rauschert, S.; Raubenheimer, K.; Melton, P.E.; Huang, R.C. Machine learning and clinical epigenetics: A review of challenges for diagnosis and classification. Clin. Epigenetics 2020, 12, 51.
29. Bosse, S.; Maniry, D.; Muller, K.R.; Wiegand, T.; Samek, W. Deep Neural Networks for No-Reference and Full-Reference Image Quality Assessment. IEEE Trans. Image Process. 2018, 27, 206–219.
30. Mazzocco, T.; Hussain, A. Novel logistic regression models to aid the diagnosis of dementia. Expert Syst. Appl. 2012, 39, 3356–3361.
31. Lu, J.; Song, E.; Ghoneim, A.; Alrashoud, M. Machine learning for assisting cervical cancer diagnosis: An ensemble approach. Futur. Gener. Comput. Syst. 2020, 106, 199–205
32. Solan, Z.; Horn, D.; Ruppin, E.; Edelman, S. Unsupervised learning of natural languages. Proc. Natl. Acad. Sci. USA 2005, 102, 11629–11634.
33. Karpischek, S.; Michahelles, F.; Fleisch, E. Detecting incorrect product names in online sources for product master data. Electron. Mark. 2014, 24, 151–160.
34. Deo, R.C. Machine Learning in Medicine. Circulation 2015, 132, 1920–1930.
35. Alanazi, H.O.; Abdullah, A.H.; Qureshi, K.N. A Critical Review for Developing Accurate and Dynamic Predictive Models Using Machine Learning Methods in Medicine and Health Care. J. Med. Syst. 2017, 41, 69.
36. Singh, A.; Mehta, J.C.; Anand, D.; Nath, P.; Pandey, B.; Khamparia, A. An intelligent hybrid approach for hepatitis disease diagnosis: Combining enhanced k -means clustering and improved ensemble learning. Expert Syst. 2020, 38, e12526.
37. Goodfellow, I.; Bengio, Y.; Courville, A. Deep Learning, 1st ed.; MIT Press: Cambridge, MA, USA, 2016